We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Immuno-Capture Technology Optimized for Mass Spectrometer Detection

By Biotechdaily staff writers
Posted on 10 Apr 2007
A next-generation immuno-capture technology has been optimized for mass spectrometer (MS) detection. More...
Immuno-catch is a powerful alternative to slower, low-yield immunoprecipitation assays. The novel technology offers a promise of molecular diagnostics for the detection using standard MS and gel technologies and new capabilities for advanced peptide and protein research.

The new kit consists of streptavidin-coated 96 well microplates and all the necessary buffers for binding and elution from the plate. The streptavidin coating procedure provides a high binding capacity for biotinylated capture agents, including antibodies, but also an extremely robust coating to allow easy elution of captured analytes. These qualities provide a high-throughput, multiplex format for the enrichment of specific target proteins and peptides from complex biological samples (such as blood serum).

PerkinElmer Life and Analytical Sciences (Waltham, MA, USA) developed the new kit, which is called the Immuno-catch kit. In addition to conventional immunoassays of intact proteins, the kit was designed to meet the unique requirements of investigators interested in the low-molecular weight peptidomic environment. Researchers in the emerging discipline of peptidomics are very interested in peptide fragments as important markers of cellular signals and as potential markers of diagnostic information.

PerkinElmer is currently collaborating with Drs. Lance Liotta and Emanuel Petricoin, co-directors of the Center for Applied Proteomics and Molecular Medicine at George Mason University (Fairfax County, VA, USA) for the investigation of possible clinical utility of peptidomics and Immuno-catch. According to Dr Liotta, "The Immuno-catch platform provides a critical component for our ongoing alliance with PerkinElmer to explore the peptidome, which we hypothesize to hold untapped and significant diagnostic potential.

In addition to conventional immunoassays of intact proteins, the Immuno-catch kit was designed to meet the unique requirements of investigators interested in the low-molecular weight peptidomic environment. Researchers in the emerging discipline of peptidomics have great interest in peptide fragments as important markers of cellular signals and as potential markers of diagnostic information.


Related Links:
PerkinElmer

New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
New
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: Pathlight combines WGS and dPCR to identify and longitudinally track large‑scale genomic changes, known as structural variants (photo courtesy of SAGA Diagnositcs)

Roche Affiliate Expands MRD Portfolio with SAGA Acquisition

Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.